New CAR T cell candidate for multiple myeloma has shown an 85% overall response rate and 71% complete response/stringent complete response at the therapeutic dose from the first 20 patients in an ongoing phase 1b relapsed/refractory multiple myeloma ongoing clinical trial. Additionally, this could be amongst the first CAR products to be administered in the out-patient setting from the start.

https://m-jpost-com.cdn.ampproject.org/c/s/m.jpost.com/health-and-wellness/article-734091/amp